Company: SCLXW
Filing Date: 2025-09-29
Form Type: 424B3
Source: 0001193125-25-221020
Chunk: 119

Company: Scilex Holding Co
Filing Date: 2025-09-29
Form: 424B3
Chunk 119
---
 is intended to provide growth capital to
Datavault to accelerate its supercomputing infrastructure, expand independent data exchanges, and unlock new revenue streams.

Datavault AI’s patented
platform is positioned to capture value across biotech, energy, and entertainment markets, as the global AI market is projected to reach $1.8 trillion by 2030 and the life sciences analytics market was estimated at $35.69 billion in 2024,
forecasted to grow at an 11.4% CAGR through 2030. By leveraging Web 3.0, blockchain-secured data trading, and AI-driven analytics, the company delivers secure, scalable solutions addressing trust, data
integrity, and monetization challenges.

The strategic investment is intended to capture growth in the biotech data monetization market, which is expected to reach
a market size of $30-50 billion by 2024. Scilex intends to leverage its expertise in the biotech and pharmaceutical space to create a potential marketplace for the Real-World Assets (RWA) in the biotech
and pharmaceutical industry that are tokenized on a blockchain to represent their ownership in digital form.

Under the terms of the purchase agreement between
Datavault and Scilex, Scilex is expected to receive up to an aggregate of 278,914,094 shares of Datavault common stock (at an effective purchase price of $0.5378 per share) ( subject to adjustment for stock splits and similar transactions), with
15,000,000 shares to be issued at the closing of the initial tranche of Scilex’s investment and the remainder to be issued in the second tranche in the form of a pre-funded warrant without beneficial
ownership limitations to be issued to Scilex following the approval by Datavault’s stockholders of, among other things, the issuance of Datavault shares to Scilex in excess of 19.99% of Datavault’s total
pre-financing shares outstanding. Datavault’s board and management remain unchanged, though Scilex will have the right to nominate two directors to the Company’s board for so long as Scilex
maintains beneficial ownership of at least 10% of the Company’s common stock, and the right to nominate one director for

Page | 1

so long as Scilex maintains beneficial ownership of at least 5% but no more than 10% of the Company’s common stock.

Henry Ji, Ph.D., CEO,